JP2007314540A5 - - Google Patents

Download PDF

Info

Publication number
JP2007314540A5
JP2007314540A5 JP2007138358A JP2007138358A JP2007314540A5 JP 2007314540 A5 JP2007314540 A5 JP 2007314540A5 JP 2007138358 A JP2007138358 A JP 2007138358A JP 2007138358 A JP2007138358 A JP 2007138358A JP 2007314540 A5 JP2007314540 A5 JP 2007314540A5
Authority
JP
Japan
Prior art keywords
isofagomine
tartrate
isofagomine tartrate
compound
purity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007138358A
Other languages
English (en)
Japanese (ja)
Other versions
JP5292605B2 (ja
JP2007314540A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2007314540A publication Critical patent/JP2007314540A/ja
Publication of JP2007314540A5 publication Critical patent/JP2007314540A5/ja
Application granted granted Critical
Publication of JP5292605B2 publication Critical patent/JP5292605B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2007138358A 2006-05-24 2007-05-24 イソファゴミンの酒石酸塩および使用方法 Expired - Fee Related JP5292605B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80802006P 2006-05-24 2006-05-24
US60/808020 2006-05-24
US89071907P 2007-02-20 2007-02-20
US60/890719 2007-02-20

Publications (3)

Publication Number Publication Date
JP2007314540A JP2007314540A (ja) 2007-12-06
JP2007314540A5 true JP2007314540A5 (enExample) 2010-07-01
JP5292605B2 JP5292605B2 (ja) 2013-09-18

Family

ID=38462442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007138358A Expired - Fee Related JP5292605B2 (ja) 2006-05-24 2007-05-24 イソファゴミンの酒石酸塩および使用方法

Country Status (14)

Country Link
US (2) US7501439B2 (enExample)
EP (1) EP1860101B1 (enExample)
JP (1) JP5292605B2 (enExample)
AT (1) ATE504570T1 (enExample)
AU (1) AU2007202359B2 (enExample)
BR (1) BRPI0706114A2 (enExample)
CA (1) CA2590122C (enExample)
DE (1) DE602007013648D1 (enExample)
DK (1) DK1860101T3 (enExample)
IL (1) IL183415A (enExample)
MX (1) MX2007006175A (enExample)
PL (1) PL1860101T3 (enExample)
PT (1) PT1860101E (enExample)
WO (1) WO2007140212A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006254796B2 (en) * 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
BRPI0713442A2 (pt) 2006-06-23 2012-03-06 Amicus Therapeutics, Inc. Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase
WO2008144773A1 (en) 2007-05-22 2008-11-27 Amicus Therapeutics, Inc. New method for preparing isofagomine and its derivatives
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2009314447A1 (en) * 2008-11-14 2010-05-20 Neuraltus Pharmaceuticals, Inc. Compositions and methods for the treatment of altered alpha-synuclein function
CN109172813B (zh) 2009-07-28 2022-09-02 武田药品工业株式会社 用于治疗戈谢病的组合物和方法
RU2608520C2 (ru) * 2009-10-19 2017-01-19 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
LT2490532T (lt) 2009-10-19 2017-03-27 Amicus Therapeutics, Inc. Naujos kompozicijos centrinės nervų sistemos degeneratyvinių sutrikimų profilaktikai ir (arba) gydymui
DK2707101T3 (da) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
AU2013202368B2 (en) 2012-01-25 2016-06-16 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
AU2013225816B2 (en) 2012-03-02 2017-10-26 Takeda Pharmaceutical Company Limited Compositions and methods for treating Type III Gaucher Disease
ES2924829T3 (es) 2012-03-27 2022-10-11 Amicus Therapeutics Inc Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosómicas y/o trastornos degenerativos del sistema nervioso central
JP2015512913A (ja) 2012-03-28 2015-04-30 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
DE102017103346A1 (de) * 2017-02-17 2018-08-23 Lts Lohmann Therapie-Systeme Ag Strukturierte orodispergierbare Filme
CN111278439A (zh) * 2017-10-26 2020-06-12 夏尔人类遗传性治疗公司 包含葡萄糖脑苷脂酶和异烟肼的调配物
MX2020014082A (es) 2018-06-27 2021-04-13 Proteostasis Therapeutics Inc Compuestos que mejoran la actividad del proteasoma.
JP7551087B2 (ja) 2018-06-27 2024-09-17 キネタ, インコーポレイテッド プロテアソーム活性増強化合物
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
JP7642561B2 (ja) * 2019-04-25 2025-03-10 武田薬品工業株式会社 イソファゴミン塩、その使用方法および製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844102A (en) * 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A

Similar Documents

Publication Publication Date Title
JP2007314540A5 (enExample)
CA2315262C (en) Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
TWI630194B (zh) 雙環止痛化合物
JP2008509953A (ja) 4−[[(7r)−8−シクロペンチル−7−エチル−5,6,7,8−テトラヒドロ−5−メチル−4−6−オキソ−2−ピペリジニル]アミノ]−3−メトキシ−n−(1−メチル−4−ピペリジニル)ベンズアミドの水和物及び多形、その製造方法、並びにその薬物としての使用
AU2010280497B2 (en) Anhydrate of tiotropium bromide
US8691839B2 (en) Aminotetraline derivatives
CA2673566A1 (en) Preparation and utility of ccr5 inhibitors
JP2011529480A (ja) ラサジリンメシレートの多型
JP2004534802A (ja) 重水素化N−及びα−置換ジフェニルアルコキシ酢酸アミノアルキルエステル並びにこれを含有する医薬品
KR20150017734A (ko) 플루오로치환된 (3r,4r,5s)-5-구아니디노-4-아세트아미도-3-(펜탄-3-일옥시)사이클로헥센-1-카복실릭 엑시드, 이의 에스테르 및 이의 용도
US20110269838A1 (en) Novel processes and pure polymorphs
MX2013010634A (es) Cristal mixto de agomelatina (forma-viii), sus metodos de preparacion y aplicaciones y composiciones farmaceuticas que le contienen.
US12378201B2 (en) Histone demethylase inhibitors for treating cancers
JP2013509357A (ja) 3−(置換ジヒドロイソインドール−2−イル)−2,6−ピペリジンジオン多結晶体及び薬用組成物
JP2019203010A (ja) 4−[2−ジメチルアミノ−1−(1−ヒドロキシシクロヘキシル)エチル]フェニル4−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用
US8754129B2 (en) Crystalline vorinostat form VI
US8193217B2 (en) Polymorphic form of granisetron hydrochloride and methods of making the same
US20230365521A1 (en) Compounds for increasing the nicotinamide adenine dinucleotide in a subject and methods of use thereof
WO2024081789A2 (en) Histone demethylase inhibitors for treating cancers
CN101365448A (zh) 包含阿片样物质拮抗的组合物剂
EP2177221A1 (en) Process for the preparation of substantially optically pure Repaglinide and precursors thereof
AU2003212040C1 (en) Substituted Cyclopentane And Cyclopentene Compounds Useful As Neuraminidase Inhibitors
NZ614326A (en) Substituted n-aryl pyridinones
NZ614326B2 (en) Substituted n-aryl pyridinones
HK1181769A (en) Process for the preparation of glycopyrronium chloride